Calamos Advisors LLC Purchases 107,931 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Calamos Advisors LLC grew its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 25.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 533,837 shares of the biotechnology company's stock after purchasing an additional 107,931 shares during the quarter. Calamos Advisors LLC owned 0.22% of ADMA Biologics worth $10,591,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of ADMA Biologics by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock worth $312,109,000 after acquiring an additional 80,302 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of ADMA Biologics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company's stock worth $93,187,000 after acquiring an additional 50,399 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of ADMA Biologics by 16.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after acquiring an additional 643,661 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of ADMA Biologics by 2.8% in the 4th quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company's stock worth $64,654,000 after acquiring an additional 102,692 shares during the last quarter. Finally, Oberweis Asset Management Inc. grew its holdings in shares of ADMA Biologics by 15.0% in the 4th quarter. Oberweis Asset Management Inc. now owns 3,342,560 shares of the biotechnology company's stock worth $57,325,000 after acquiring an additional 435,480 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Down 0.4%

ADMA traded down $0.07 during trading on Tuesday, reaching $17.81. 1,915,732 shares of the stock traded hands, compared to its average volume of 3,690,459. The stock has a market cap of $4.25 billion, a price-to-earnings ratio of 20.95 and a beta of 0.43. ADMA Biologics Inc has a fifty-two week low of $10.21 and a fifty-two week high of $25.67. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. The stock's 50-day simple moving average is $19.99 and its two-hundred day simple moving average is $18.73.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same period in the prior year, the firm earned $0.08 EPS. ADMA Biologics's quarterly revenue was up 40.2% on a year-over-year basis. As a group, equities research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analyst Ratings Changes

ADMA has been the topic of a number of research analyst reports. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial lifted their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th.

Insiders Place Their Bets

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the sale, the director owned 87,330 shares of the company's stock, valued at $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the sale, the director directly owned 478,194 shares of the company's stock, valued at $10,190,314.14. This represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Insiders sold 464,621 shares of company stock valued at $9,644,269 over the last quarter. Insiders own 3.70% of the company's stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.